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1. Introduction 
Clinical interest in the possible use of somatostatin 
(SS) to inhibit glucagon secretion in diabetes mellitus 
has led to the search for analogs of SS with greater and/ 
or more selective activities and with a prolonged biologic 
effectiveness. Several SS analogs with either a higher 
potency in suppressing insulin and glucagon secretion 
[D-Trps]-SS [l] or a greater effect for inhibition of 
glucagon than insulin [DC~S’~]-SS [2] and [DTrpS 
D-C~S’~]-SS [3,4] have now been developed. In the 
course of a study designed to compare the relative 
efficacies of the foregoing analogs as glucagon 
suppressants in alloxan diabetic dogs, it was noted 
that plasma samples were less turbid after a subcuta- 
neous injection of the peptides than after a saline 
control. In order to test if there is an influence of SS 
and its analogs on postabsorptive triglyceride levels, 
we have measured plasma triglyceride levels in the 
plasma of insulin deprived fasted alloxan diabetic dogs 
after a single injection of SS, [D-Trps]-SS, [DTrp*- 
DCys’4]-SS, or saline, respectively. 
2. Materials and methods 
Seven chronic alloxan diabetic dogs weighing 
between 19 kg and 25 kg were used for the various 
experiments. Insulin treatment was discontinued 40 h 
before the start of an experiment, and food was with- 
held for 20 h. The dogs received, on four different 
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experimental days separated by at least a seven day 
interval, a subcutaneous (s.c.) injection of either 1 mg 
[D-Trps]-SS (n = 5), 1 mg [DTrp8-DCys’4]-SS (n = 5), 
1 mg SS (n = 7), all dissolved in 2 ml saline, or a 2 ml 
saline (n = 4) control injection. Blood samples were 
obtained at frequent intervals from a foreleg vein 
before and after an injection. 
Triglyceride concentrations were measured by an 
enzymatic method of Eggstein and Kreutz [S] using a 
commercial kit (Boehringer Mannheim). For statistical 
analysis of the data, the Student -test for two groups 
was used because not every dog was studied in every 
experimental protocol. 
3. Results and discussion 
The effects of SS and the SS analogs upon 
triglyceride levels are shown in fig. 1. In the control 
group, mean triglyceride concentrations increased 
from a baseline level of 65.9 f 4.3 mg% by about 20 
mg% after 3 h. Following [DTrp*]-SS injection, 
triglycerides declined about 10 mg% from a baseline 
of 64.8 f 3.9 mg% while after the injection of SS and 
[D-Trp8-D-Cys14]-SS, triglyceride levels declined, 
respectively, 15 mg% from a mean baseline of 
53.3 + 3.0 mg% and 24 mg% from a baseline level of 
65.6 i4.3 mg%. The triglyceride-lowering effect of the 
agents was not related to their glucagon-reducing 
activity which was greatest for [D-Trp8-D-Cys’4]-SS 
and [DTrp*]-SS [6]. 
Sakurai et al. [7] and, more recently, Pointer et al. 
[8] have reported that SS reduces postprandial 
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Fig.1. Changes in mean plasma triglyceride levels (+ SEM) after a subcutaneous (s.c.) injection of 1 mg somatostatin (SS), 1 mg 
[DTrp8]SS, 1 mg [ D-T~~*-DC~S’~]-SS and2 ml saline, respectively. 
triglyceride levels. The present study is the first demon- 
stration of an effect on triglyceride levels in the 
postabsorptive state, suggesting an influence of SS and 
its analogs on endogenous triglyceride turnover. The 
mechanism of the apparent triglyceride lowering action 
of these agents in insulin-deprived alloxan diabetic dogs 
remains to be determined. 
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